ETON

Eton Pharmaceuticals, Inc. (ETON) | Rumor.io

Eton Pharmaceuticals

ETON

Attention (50-day avg)0%

Attention rank (50-day avg)#846

Bullish sentiment (50-day avg)95%

Price to earnings ratio147.9

Market capitalization1.7B

Earnings per share0.39

Dividend yield (TTM)—

Revenue (annual)80M

Net income (annual)-4.6M

Social

What share of all stock conversation is about ETON?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Aug 17

ETON Pharmaceuticals reported a huge Q2 beat, with product sales YoY +99% and net income driven by the DESMODA launch. The stock surged +44.26% to $58.86 intraday.
The company's strong earnings were driven by the successful integration of Hemangeol and the launch of DESMODA, with product sales exceeding expectations.
ETON's earnings beat and product sales growth have led to a reiterate BUY rating and a raised price target to $76.

Generated by AI

Sentiment

Of the messages about ETON that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	43.48%	58.06% -41.21	88.77% -4.8
Bearish	—	56.52%	41.94% +41.21	11.23% +4.8

Bullish· Feb 25

$ETON has strong support at $17, with almost 80% of positions in profit, and is likely to stabilize soon.
The FDA decision on ET-600 is a key catalyst for $ETON, which could lead to a significant price move.
$ETON has a strong growth trajectory, with the potential for profitability and another drug approval, which could drive the stock price up to $25-30 in the next 30-45 days.

Bearish· Jul 19

The $ETON price has failed to move higher despite FDA approval, suggesting that the market may have already priced in the news.
The stock's performance is being driven by short sellers, who are likely to continue to pressure the price downward.
Despite FDA approval, $ETON is trading lower than it was before the news, and its price action is not consistent with the typical reaction to a positive development.

Generated by AI

Topics

Of the messages about ETON that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	91.4%	75.07%
Technical Analysis	—	100%	8.6%	17.46%
Analysts	—	0%	0%	2.25%
Earnings	—	0%	0%	5.21%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	0%

Announcements· Aug 11

Eton Pharmaceuticals reported Q2 2023 financial results, with total revenue of $12M, net income of $4.6M, and $21.6M of cash on hand.
The company launched Betaine Anhydrous and achieved record product sales, with product sales and royalty revenue up 175% from Q2 2022 and 22% from Q1 2023.
Eton Pharmaceuticals increased its revenue expectation to approximately $30 million in total revenue for the year, with a goal of having 10 commercial rare disease products on the market by the end of 2025.

Controversies· May 28

Eton Pharmaceuticals (ETON) received a Complete Response Letter (CRL) from the US FDA for its Dehydrated Alcohol Injection, a treatment for methanol poisoning.
The FDA determined that the application cannot be approved in its present form, sending Eton Pharmaceuticals' stock tumbling.
The FDA's rejection of Eton Pharmaceuticals' Dehydrated Alcohol Injection application raises concerns about the company's ability to bring the treatment to market.

Generated by AI

Community

Of the messages about ETON, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	76.35%	87.43%	62.19%
Newcomers	—	23.65%	12.57%	37.81%

Regulars· Aug 14

Eton Pharmaceuticals reports record revenue of $37.6 million in Q2 2026, a 99% growth over Q2 2025, and raises full year revenue guidance to exceed $145 million.
The company has expanded its infantile hemangioma franchise with the acquisition of late-stage product candidate ASN-001, and has submitted a Prior Approval Supplement to the FDA to expand the indication of KHINDIVI.
Eton Pharmaceuticals has also received FDA Fast Track designation for endocrinology development product AMGLIDIA and acquired U.S. commercialization rights to orphan drug IMPAVIDO.

Newcomers· Aug 14

An analyst believes Eton Pharma's raised guidance is conservative, leading to a potential best-ever day for the stock.
The company is expected to discuss its Q2 filing and growth initiatives during an upcoming call, with a focus on its first-half momentum.
Eton Pharma's management is engaging shareholders more directly, likely due to the stock's recent performance and increased investor interest.

Generated by AI

During the lightning round of the August 26 Mad Money episode, a caller asked whether it is time to “cut it off” or if Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has more potential given that they bought the shares at $30 and the stock is now above $60. In response, Jim Cramer said: I think you take […]

1mo agoYahoo Finance

Eton Pharmaceuticals Insider Sold Shares Worth $2,953,572, According to a Recent SEC Filing

1mo agoYahoo Finance

Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference

DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host 1x1 meetings on September 9, 2026 at the 2026 Wells Fargo Healthcare Conference being held September 8-10, 2026 in Boston, MA. To schedule a 1x1 meeting with the Company, please contact your

1mo agoYahoo Finance

Insider Unloading: David Krempa Sells Options, Realizes $1.43M

1mo agoBenzinga

Also Discussed

Investors talking about ETON also mention

#	Name	Attention
1	Fennec Pharmaceuticals Inc.FENC	0%0
2	Sol-Gel Technologies Ltd.SLGL	0%0
3	MediWound Ltd.MDWD	0%0
4	Harrow Inc.HROW	0%0
5	PRVB - Provention Bio, Inc.	——
6	Ardelyx IncARDX	0.01%+0.01
7	Verrica Pharmaceuticals Inc.VRCA	0%0
8	Aquestive Therapeutics Inc.AQST	0%+0
9	Lipocine Inc.LPCN	0%new
10	Liquidia CorporationLQDA	0.01%0

Eton Pharmaceuticals, Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare and underserved diseases. Eton Pharmaceuticals, Inc. offers a commercial portfolio that includes therapies for adrenal insufficiency, severe primary IGF-1 deficiency, Wilson disease, phenylketonuria, homocystinuria, tyrosinemia type 1, and central diabetes insipidus, along with prescription products such as oral suspensions, injectable formulations, and oral solutions. The company also works across pediatric and adult care settings, supporting medications used in endocrine, metabolic, and other niche therapeutic areas. Based in Deer Park, Illinois, Eton Pharmaceuticals, Inc. plays a focused role in the rare-disease market by bringing specialized medicines to patients and healthcare providers through a mix of in-licensed products, commercial launches, and targeted product development.

Website

Location

21925 W. Field Parkway

Deer Park, IL, 60010-7278

United States

Social

What share of all stock conversation is about ETON?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Aug 17

ETON Pharmaceuticals reported a huge Q2 beat, with product sales YoY +99% and net income driven by the DESMODA launch. The stock surged +44.26% to $58.86 intraday.
The company's strong earnings were driven by the successful integration of Hemangeol and the launch of DESMODA, with product sales exceeding expectations.
ETON's earnings beat and product sales growth have led to a reiterate BUY rating and a raised price target to $76.

Generated by AI

Sentiment

Of the messages about ETON that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	43.48%	58.06% -41.21	88.77% -4.8
Bearish	—	56.52%	41.94% +41.21	11.23% +4.8

Bullish· Feb 25

$ETON has strong support at $17, with almost 80% of positions in profit, and is likely to stabilize soon.
The FDA decision on ET-600 is a key catalyst for $ETON, which could lead to a significant price move.
$ETON has a strong growth trajectory, with the potential for profitability and another drug approval, which could drive the stock price up to $25-30 in the next 30-45 days.

Bearish· Jul 19

The $ETON price has failed to move higher despite FDA approval, suggesting that the market may have already priced in the news.
The stock's performance is being driven by short sellers, who are likely to continue to pressure the price downward.
Despite FDA approval, $ETON is trading lower than it was before the news, and its price action is not consistent with the typical reaction to a positive development.

Generated by AI

Topics

Of the messages about ETON that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	91.4%	75.07%
Technical Analysis	—	100%	8.6%	17.46%
Analysts	—	0%	0%	2.25%
Earnings	—	0%	0%	5.21%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	0%

Announcements· Aug 11

Eton Pharmaceuticals reported Q2 2023 financial results, with total revenue of $12M, net income of $4.6M, and $21.6M of cash on hand.
The company launched Betaine Anhydrous and achieved record product sales, with product sales and royalty revenue up 175% from Q2 2022 and 22% from Q1 2023.
Eton Pharmaceuticals increased its revenue expectation to approximately $30 million in total revenue for the year, with a goal of having 10 commercial rare disease products on the market by the end of 2025.

Controversies· May 28

Eton Pharmaceuticals (ETON) received a Complete Response Letter (CRL) from the US FDA for its Dehydrated Alcohol Injection, a treatment for methanol poisoning.
The FDA determined that the application cannot be approved in its present form, sending Eton Pharmaceuticals' stock tumbling.
The FDA's rejection of Eton Pharmaceuticals' Dehydrated Alcohol Injection application raises concerns about the company's ability to bring the treatment to market.

Generated by AI

Community

Of the messages about ETON, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	76.35%	87.43%	62.19%
Newcomers	—	23.65%	12.57%	37.81%

Regulars· Aug 14

Eton Pharmaceuticals reports record revenue of $37.6 million in Q2 2026, a 99% growth over Q2 2025, and raises full year revenue guidance to exceed $145 million.
The company has expanded its infantile hemangioma franchise with the acquisition of late-stage product candidate ASN-001, and has submitted a Prior Approval Supplement to the FDA to expand the indication of KHINDIVI.
Eton Pharmaceuticals has also received FDA Fast Track designation for endocrinology development product AMGLIDIA and acquired U.S. commercialization rights to orphan drug IMPAVIDO.

Newcomers· Aug 14

An analyst believes Eton Pharma's raised guidance is conservative, leading to a potential best-ever day for the stock.
The company is expected to discuss its Q2 filing and growth initiatives during an upcoming call, with a focus on its first-half momentum.
Eton Pharma's management is engaging shareholders more directly, likely due to the stock's recent performance and increased investor interest.

Generated by AI

Eton Pharmaceuticals

Social

Aug 17

Bullish· Feb 25

Bearish· Jul 19

Announcements· Aug 11

Controversies· May 28

Regulars· Aug 14

Newcomers· Aug 14

Eton Pharmaceuticals launches IMPAVIDO for leishmaniasis

PAUL MAIER V At Eton Pharmaceuticals Executes Options Exercise, Realizing $2.84M

Jim Cramer Explains Mad Money Caller How to Handle Eton Pharmaceuticals (ETON)

Eton Pharmaceuticals Insider Sold Shares Worth $2,953,572, According to a Recent SEC Filing

Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference

Insider Unloading: David Krempa Sells Options, Realizes $1.43M

Also Discussed

Eton Pharmaceuticals, Inc.

Company Information

Location

Eton Pharmaceuticals launches IMPAVIDO for leishmaniasis

PAUL MAIER V At Eton Pharmaceuticals Executes Options Exercise, Realizing $2.84M

Jim Cramer Explains Mad Money Caller How to Handle Eton Pharmaceuticals (ETON)

Eton Pharmaceuticals Insider Sold Shares Worth $2,953,572, According to a Recent SEC Filing

Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference

Insider Unloading: David Krempa Sells Options, Realizes $1.43M

Also Discussed

Social

Aug 17

Bullish· Feb 25

Bearish· Jul 19

Announcements· Aug 11

Controversies· May 28

Regulars· Aug 14

Newcomers· Aug 14